Roth Capital started coverage on shares of CryoPort (NASDAQ:CYRX) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating and a $12.50 price target on the consumer goods maker’s stock. Roth Capital’s target price points to a potential upside of 77.56% from the company’s current price.
A number of other brokerages have also issued reports on CYRX. Janney Montgomery Scott upped their price objective on shares of CryoPort from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, October 3rd. Cowen reissued an “outperform” rating and issued a $11.00 price objective (up previously from $7.50) on shares of CryoPort in a report on Tuesday, September 12th. Finally, Needham & Company LLC upped their price objective on shares of CryoPort from $8.50 to $10.00 and gave the company a “buy” rating in a report on Wednesday, August 30th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. CryoPort presently has an average rating of “Buy” and an average target price of $33.50.
Shares of CryoPort (CYRX) traded down $0.07 on Thursday, hitting $7.04. 167,578 shares of the company were exchanged, compared to its average volume of 127,383. CryoPort has a 12-month low of $1.96 and a 12-month high of $10.40.
ILLEGAL ACTIVITY NOTICE: “CryoPort (CYRX) Coverage Initiated at Roth Capital” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://weekherald.com/2017/12/02/cryoport-cyrx-coverage-initiated-at-roth-capital.html.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.